DexCom, Inc. (NASDAQ:DXCM) – Research analysts at William Blair upped their Q4 2017 EPS estimates for DexCom in a research report issued on Tuesday. William Blair analyst M. Kaczor now forecasts that the medical device company will post earnings per share of $0.06 for the quarter, up from their prior forecast of $0.02. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.56) EPS.
DXCM has been the subject of several other reports. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Wedbush reissued a “buy” rating and issued a $76.00 target price on shares of DexCom in a research report on Wednesday, October 4th. Barclays initiated coverage on shares of DexCom in a research report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 target price for the company. Raymond James Financial downgraded shares of DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $69.00 target price (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. DexCom has a consensus rating of “Buy” and an average price target of $72.31.
Shares of DexCom (NASDAQ DXCM) opened at $58.60 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. The company has a market cap of $5,090.00, a P/E ratio of -102.81 and a beta of 0.31. DexCom has a 1 year low of $42.62 and a 1 year high of $88.80.
A number of institutional investors have recently modified their holdings of DXCM. Schwab Charles Investment Management Inc. boosted its holdings in DexCom by 13.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 256,848 shares of the medical device company’s stock valued at $18,789,000 after purchasing an additional 29,608 shares during the period. Comerica Bank boosted its holdings in DexCom by 8.7% in the 2nd quarter. Comerica Bank now owns 17,586 shares of the medical device company’s stock valued at $1,225,000 after purchasing an additional 1,403 shares during the period. Tredje AP fonden bought a new stake in DexCom in the 2nd quarter valued at $331,000. Franklin Resources Inc. boosted its holdings in DexCom by 2.1% in the 2nd quarter. Franklin Resources Inc. now owns 971,440 shares of the medical device company’s stock valued at $71,060,000 after purchasing an additional 19,940 shares during the period. Finally, Stephens Inc. AR boosted its holdings in DexCom by 78.8% in the 2nd quarter. Stephens Inc. AR now owns 7,135 shares of the medical device company’s stock valued at $522,000 after purchasing an additional 3,145 shares during the period.
In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Andrew K. Balo sold 6,490 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total transaction of $389,400.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,140 shares of company stock valued at $2,158,576. Insiders own 1.70% of the company’s stock.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/equities-analysts-issue-forecasts-for-dexcom-inc-s-q4-2017-earnings-dxcm.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.